News | July 06, 2022
CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
It is developing the drug candidate to potentially treat immunological diseases
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The plan is to advance innovative therapies to drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
